Literature DB >> 19389212

Sensitivity of two hepatitis B virus, hepatitis C virus (HCV), and human immunodeficiency virus (HIV) nucleic acid test systems relative to hepatitis B surface antigen, anti-HCV, anti-HIV, and p24/anti-HIV combination assays in seroconversion panels.

Azzedine Assal1, Valérie Barlet, Marie Deschaseaux, Isabelle Dupont, Pierre Gallian, Cathy Guitton, P Morel, Harry van Drimmelen, Bernard David, Nico Lelie, Philippe De Micco.   

Abstract

BACKGROUND: Accurate determination of the infectious window period (IWP) that remains with individual-donation (ID) or minipool (MP) NAT compared to those with serology assays is essential for residual risk estimations. STUDY DESIGN AND METHODS: The relative sensitivity of the Procleix Tigris system (Gen-Probe/Chiron) used in ID-NAT format and cobas s 201 (Roche Molecular Systems) applied in 1:6 diluted samples to mimic six-minipool (MP6) nucleic acid test (NAT) was assessed by quadruplicate testing of five seroconversion panels per marker. A mathematical analysis based on the log-linear increase of viremia in the ramp-up phase, as established with bDNA 3.0 assays enabled estimation of the IWP for human immunodeficiency virus (HIV) and hepatitis B virus (HBV) assays.
RESULTS: The mean IWPs were Tigris HIV RNA 5.5 days, s 201 (1:6) HIV RNA 7.4 days, GenScreen Plus p24/anti-HIV 17.8 days, PRISM anti-HIV 19.0 days, Tigris HBV DNA 20.6 days, s 201 (1:6) HBV DNA 22.6 days, Bio-Rad hepatitis B surface antigen (HBsAg) 37.8 days, and PRISM HBsAg 35.5 days. At estimated 50 percent NAT seroconversion rates, s 201 (1:6) and Tigris showed mean window-period reduction times (WPRTs) of 30.5 to 35.5 days to hepatitis C virus antibody (anti-HCV) assays, 10.4 to 13.5 days to anti-HIV, or combination p24/anti-HIV assays and 12.8 to 17.2 days to HBsAg assays.
CONCLUSIONS: Tigris ID-NAT detected HIV RNA 2 days earlier than s 201 MP6-NAT, but the difference in sensitivity between the two NAT systems was not significant in HBV seroconversion panels. Insufficient seroconversion samples were available for reliable modeling of WPRT in early HCV infection, but 1.4 to 2.0 days could be predicted by translating analytical sensitivity data. Both multiplex NAT systems demonstrate significant WPRTs compared to (combined) antigen and antibody assays.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19389212     DOI: 10.1111/j.1537-2995.2008.01966.x

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  13 in total

1.  Quarantine Plasma: Quo vadis?

Authors:  W Kurt Roth
Journal:  Transfus Med Hemother       Date:  2010-05-25       Impact factor: 3.747

2.  A conceptual model of interventions to increase diagnosis of acute HIV infection and reduce forward transmission.

Authors:  Andrew E Petroll; Steven D Pinkerton
Journal:  AIDS Behav       Date:  2011-11

3.  Sensitivity of individual-donation and minipool nucleic acid amplification test options in detecting window period and occult hepatitis B virus infections.

Authors:  Marion Vermeulen; Charl Coleman; Josephine Mitchel; Ravi Reddy; Harry van Drimmelen; Tracy Ficket; Nico Lelie
Journal:  Transfusion       Date:  2013-04-29       Impact factor: 3.157

Review 4.  Hepatitis B transmission by cell and tissue allografts: how safe is safe enough?

Authors:  Pilar Solves; Vicente Mirabet; Manuel Alvarez
Journal:  World J Gastroenterol       Date:  2014-06-21       Impact factor: 5.742

5.  Surface antigen-negative hepatitis B virus infection in Dutch blood donors.

Authors:  R W Lieshout-Krikke; M W A Molenaar-de Backer; P van Swieten; H L Zaaijer
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-09-13       Impact factor: 3.267

6.  Development of a new duplex real-time polymerase chain reaction assay for hepatitis B viral DNA detection.

Authors:  Shipeng Sun; Shuang Meng; Rui Zhang; Kuo Zhang; Lunan Wang; Jinming Li
Journal:  Virol J       Date:  2011-05-14       Impact factor: 4.099

7.  Sufficient blood, safe blood: can we have both?

Authors:  Halvard Bönig; Michael Schmidt; Kai Hourfar; Jörg Schüttrumpf; Erhard Seifried
Journal:  BMC Med       Date:  2012-03-23       Impact factor: 8.775

8.  Viral Surveillance in Serum Samples From Patients With Acute Liver Failure By Metagenomic Next-Generation Sequencing.

Authors:  Sneha Somasekar; Deanna Lee; Jody Rule; Samia N Naccache; Mars Stone; Michael P Busch; Corron Sanders; William M Lee; Charles Y Chiu
Journal:  Clin Infect Dis       Date:  2017-10-16       Impact factor: 9.079

9.  Effectiveness of blood donor screening by HIV, HCV, HBV-NAT assays, as well as HBsAg and anti-HBc immunoassays in Germany (2008-2015).

Authors:  Sarah A Fiedler; Doris Oberle; Michael Chudy; Heinrich Scheiblauer; Olaf Henseler; Jochen Halbauer; Margarethe Heiden; Markus Funk
Journal:  Vox Sang       Date:  2019-04-22       Impact factor: 2.144

10.  An assessment of hepatitis B virus prevalence in South African young blood donors born after the implementation of the infant hepatitis B virus immunization program: Implications for transfusion safety.

Authors:  Marion Vermeulen; Ronel Swanevelder; Gert Van Zyl; Nico Lelie; Edward L Murphy
Journal:  Transfusion       Date:  2021-06-26       Impact factor: 3.337

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.